Sevabertinib, an investigational oral treatment, is under Priority Review by the FDA for patients with HER2+ non-small cell lung cancer (NSCLC) and other solid tumors harboring HER2-activating mutations. Developed through a research collaboration between Bayer and the Broad Institute of MIT and Harvard, Sevabertinib is a reversible tyrosine kinase inhibitor (TKI) specifically designed to target […]